Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01729871 · ClinicalTrials.gov registry record · Phase 3

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

A Phase 3 study of Atrial Fibrillation, sponsored by Janssen Scientific Affairs.

Completed
Registry status
Phase 3
Development phase
253
Enrollment target
20
Study locations

NCT01729871 is a Phase 3 study of Atrial Fibrillation that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 253 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01729871, a Phase 3 study of Atrial Fibrillation, has completed, sponsored by Janssen Scientific Affairs.

COMPLETED
Registry status
Phase 3
Development phase
253 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this exploratory study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult participants with non-valvular atrial fibrillation (NVAF) who undergo catheter ablation as measured by post-procedure major bleeding events.

Conditions Studied

Atrial Fibrillation

Interventions

  • DRUG rivaroxaban
  • DRUG uninterrupted vitamin K antagonist (VKA)

Study Locations (20)

California

  • - Beverly Hills
  • - Los Angeles
  • - Sacramento
  • - San Francisco

Pennsylvania

  • - Erie
  • - Hershey
  • - Philadelphia

Texas

  • - Austin
  • - Dallas

Florida

  • - Jacksonville

Illinois

  • - Maywood

Kansas

  • - Kansas City

Massachusetts

  • - Boston

Minnesota

  • - Saint Louis Park

Trial Details

FieldValue
Enrollment Target 253 participants
Start Date 2013-02
Est. Completion 2014-10
Phase Phase 3

Sponsor

Janssen Scientific Affairs

37 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01729871

The ClinicalTrials.gov registry entry for NCT01729871 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (92% lower). The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which rivaroxaban is the first listed.

NCT01729871 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT01729871 about?

NCT01729871 is a clinical study titled "A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy". The purpose of this exploratory study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult participants with non-valvular atrial fibrillation (NVAF) who undergo catheter ablation as measured by post-procedure major bleeding events.

What is the current status of trial NCT01729871?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 253 participants. The study started on 2013-02. Estimated completion is 2014-10.

What conditions does trial NCT01729871 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT01729871?

The interventions under investigation include: rivaroxaban (DRUG), uninterrupted vitamin K antagonist (VKA) (DRUG).

Who is sponsoring clinical trial NCT01729871?

This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01729871 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.